Online citations, reference lists, and bibliographies.

Proton Pump Inhibitor Use And Risk Of Dementia

Min Li, Zheng rong Luo, Sisi Yu, Zhenyu Tang
Published 2019 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
Background: Proton pump inhibitors (PPIs) are an established kind of drugs used to the treatment of most acid-related diseases. Some prospective studies have noticed that PPI use was associated with increased dementia risk. However, the results of those studies were inconsistent and controversial. This meta-analysis aims to determine the association of PPI use and risk of dementia among older people. Methods: Relevant articles were systematically identified by searching the PubMed, EMBASE, and Cochrane Library databases from inception to February 2018. Cohort studies that reported the risk of dementia or Alzheimer's disease (AD) among PPI users compared with non-PPI users were included. The quality of studies was assessed using the Newcastle-Ottawa Scale (NOS). The publication bias was detected by a funnel plot and Egger test. The meta-analysis will abstract risk estimates including relative risks (RRs), hazard ratios (HRs), and odds ratios (ORs) with a 95% confidence interval (CI) for the associations between PPI use and dementia or Alzheimer's risk. Study-specific results were pooled using a random-effects model. Results: Six cohort studies were selected finally. The pooled RRs of dementia and AD were 1.23 (95% CI: 0.90–1.67) and 1.01 (95% CI: 0.78–1.32), respectively, compared with those of non-PPI use. The Egger test and funnel plot showed no existence of publication bias. Overall, there was no statistically significant association between PPI use and risk of dementia or AD (P >.05). Conclusions: This meta-analysis suggests that there was no statistical association between PPIs use and increased risk of dementia or AD.
This paper references
Proteolytic processing and cell biological functions of the amyloid precursor protein.
B. De Strooper (2000)
10.1016/j.semerg.2016.03.020
[Proton-pump inhibitors and risk of dementia].
Antonio Alcántara Montero (2017)
Prolonged use of proton pump inhibitors and congnitive function in older adults
Herghelegiu AMGP (2016)
10.1002/pds.4043
Proton pump inhibitor prescribing patterns in the UK: a primary care database study.
Fatmah Othman (2016)
10.1111/jgh.13750
Dementia, cognitive impairment and proton pump inhibitor therapy: A systematic review
Riley Batchelor (2017)
10.1001/jama.2013.280490
Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency.
Jameson R. Lam (2013)
10.1001/jamainternmed.2015.7193
Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease.
Benjamin M. Lazarus (2016)
The association between vitamin B 12 de fi ciency and long - term use of acid lowering agents : a systematic review and meta - analysis
SB Jung (2015)
10.1016/j.ejim.2010.11.009
Prevalence and appropriateness of drug prescriptions for peptic ulcer and gastro-esophageal reflux disease in a cohort of hospitalized elderly.
Luca Pasina (2011)
10.1016/0197-2456(86)90046-2
Meta-analysis in clinical trials.
R. Dersimonian (1986)
10.1080/13607863.2018.1468411
Association between polypharmacy and dementia – A systematic review and metaanalysis
Nattawut Leelakanok (2019)
10.1001/jama.287.3.337
Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey.
D. Kaufman (2002)
10.1001/jamaneurol.2015.4931
Do Proton Pump Inhibitors Increase the Risk of Dementia?
Lewis H. Kuller (2016)
10.1136/bmj.e372
Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study
H. Khalili (2012)
10.1038/ajg.2017.196
No Association Between Proton Pump Inhibitor Use and Risk of Alzheimer’s Disease
Heidi Taipale (2017)
10.1371/journal.pone.0171006
Risk of dementia from proton pump inhibitor use in Asian population: A nationwide cohort study in Taiwan
Shu-Yu Tai (2017)
10.1016/j.gerinurse.2016.04.009
Do proton pump inhibitors cause dementia?
William Simonson (2016)
10.1186/1472-6904-10-16
Increasing polypharmacy - an individual-based study of the Swedish population 2005-2008
Bo Hovstadius (2010)
10.1001/jamainternmed.2015.7927
Adverse Effects Associated With Proton Pump Inhibitors.
Adam J Schoenfeld (2016)
10.1001/jamaneurol.2015.4791
Association of Proton Pump Inhibitors With Risk of Dementia: A Pharmacoepidemiological Claims Data Analysis.
Willy Gomm (2016)
10.1016/j.arcmed.2012.11.003
Epidemiology of dementias and Alzheimer's disease.
Ana Luisa Sosa-Ortíz (2012)
10.1371/journal.pone.0112558
The Association between the Use of Proton Pump Inhibitors and the Risk of Hypomagnesemia: A Systematic Review and Meta-Analysis
C. Park (2014)
10.1371/journal.pone.0058837
The Proton-Pump Inhibitor Lansoprazole Enhances Amyloid Beta Production
Nahuai Badiola (2013)
10.1016/j.jval.2015.09.955
Risk Factors For Dementia Diagnosis In German Primary Care Practices.
Anke Wendschlag (2015)
10.1016/j.ypmed.2004.04.047
Cobalamin: a critical vitamin in the elderly.
M. Wolters (2004)
cognitive impairment and proton pump inhibitor therapy-a systematic review
R Batchelor (2017)
10.1111/j.1365-2710.2008.00907.x
A succinct review of the general and immunological pharmacologic effects of proton pump inhibitors.
Mohammad Reza Namazi (2008)
10.1111/jgs.14956
Proton Pump Inhibitors and Risk of Mild Cognitive Impairment and Dementia
F. Goldstein (2017)
10.1001/archinte.167.9.950
Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study.
Sinem Ezgi Gulmez (2007)
10.1111/jgs.15073
Proton Pump Inhibitor Use and Dementia Risk: Prospective Population‐Based Study
S. Gray (2018)
10.1001/jama.296.24.2947
Long-term proton pump inhibitor therapy and risk of hip fracture.
Yu-Xiao Yang (2006)
Magnitude and economic effect of overuse of antisecretory therapy in the ambulatory care setting.
Joel J. Heidelbaugh (2010)
10.1007/s00406-014-0554-0
Risk of dementia in elderly patients with the use of proton pump inhibitors
B. Haenisch (2014)
10.1016/S1474-4422(11)70072-2
The projected effect of risk factor reduction on Alzheimer's disease prevalence
D. Barnes (2011)
Meta-analysis of observational
DF Stroup (2008)
10.1016/j.jns.2012.07.023
Epidemiology of dementia in Asia: Insights on prevalence, trends and novel risk factors
Joseree-Ann S. Catindig (2012)
10.1101/cshperspect.a004457
Alzheimer's disease.
D. Selkoe (2011)
10.1007/s40264-018-0638-2
The Uncertainty of the Association Between Proton Pump Inhibitor Use and the Risk of Dementia: Prescription Sequence Symmetry Analysis Using a Korean Healthcare Database Between 2002 and 2013
S. Park (2018)
Ageing and life course, Facts about ageing, World Health Organization
10.1007/s10654-010-9491-z
Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses
A. Stang (2010)
10.1001/jama.283.15.2008
Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group.
D. Stroup (2000)
10.1136/bmj.327.7414.557
Measuring inconsistency in meta-analyses
J. Higgins (2003)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar